vimarsana.com
  1. Home
  2. Live Updates
  3. சூரியன் யத் சென் பல்கலைக்கழகம் புற்றுநோய் மையம் - Breaking News

Page 5 - சூரியன் யத் சென் பல்கலைக்கழகம் புற்றுநோய் மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Most Oncology Trials Fail to Report Timely Results

email article While fewer than 40% of completed oncology trials in 2017 reported their results in a timely fashion, that percentage was eight times higher compared with a decade ago, researchers reported. Among more than 12,000 clinical trials registered in ClinicalTrials.gov, the percentage reporting results within 24 months of the primary completion date increased from 5.1% in 2007 to 39.1% in 2017 (adjusted HR 1.11 per year increase, 95% CI 1.10-1.13), according to Jun Ma, MD, of Sun Yat-sen University Cancer Center in Guangzhou, China, and colleagues. The increase in results reporting was likely associated with recent joint efforts to promote results reporting, especially mandatory reporting requirements enforced by the FDAAA [Food and Drug Administration Amendments Act] in the U.S. and similar statutory regulations in Europe, the authors wrote in

United statesVanessa piechottaJun maNina kreuzbergerMike bassettUniversity of cologneSun yat sen university cancer centerClinical trialClinical trialsDrug administrationஒன்றுபட்டது மாநிலங்களில்ஜூன் மாமைக் பாசெட்பல்கலைக்கழகம் ஆஃப் கொலோன்சூரியன் யத் சென் பல்கலைக்கழகம் புற்றுநோய் மையம்மருத்துவ சோதனை

BeiGene to Showcase Broad Clinical Portfolio at 2021 ASCO Annual Meeting

CAMBRIDGE, Mass. & BEIJING (BUSINESS WIRE) May 19, 2021 BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that clinical results and updates from its broad portfolio will be presented at the 2021 Annual Meeting of the American Society of Cancer Oncology (ASCO) being held June 4 – 8, 2021. “We are pleased to share updates from our growing clinical portfolio across solid tumors and hematologic malignancies at this year’s ASCO, including multiple novel combinations of tislelizumab with our investigational Fc-competent anti-TIGIT-antibody ociperlimab and other therapeutic agents, and the ongoing evaluation of our next-generation BTK inhibitor zanubrutinib,” commented Lai Wang, Ph.D., Global Head of R&D at BeiGene. “We believe that these presentations underscore the breadth and diversity, as well as the remarkable progress and momentum, in BeiGeneâ

United statesLin shenSoult ukpyolsiSouth koreaSouth australiaUnited kingdomMarka socinskiKeun wook leeFortunato ciardielloJie wangLai wangLingying wuTao sunRuihua xuMazyar shadmanJian li

Innovent Will Publish Multiple Clinical Data at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Han liangUnited statesHong kongInnovent biologicsBaorui liuQin xuZhiming liEli lillyXiubao renAdimab incyteJundong liNeoadjuvant resectableXiaofeng chenYi baCaicun zhouJin li

Innovent Will Publish Multiple Clinical Data at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Innovent Will Publish Multiple Clinical Data at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.

Han liangUnited statesHong kongInnovent biologicsBaorui liuQin xuZhiming liEli lillyXiubao renAdimab incyteJundong liNeoadjuvant resectableXiaofeng chenYi baCaicun zhouJin li

Lobaplatin Promising in Nasopharyngeal Cancer

Lobaplatin Promising in Nasopharyngeal Cancer
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.

United statesLisa licitraStefano cavalieriInternational cooperation project of scienceSun yat sen university cancer centreNational scienceTechnology project of guangdong provinceTechnology pillar programBristol myers squibbTechnology program of guangdong provinceNational comprehensive cancer networkInternational cooperation projectTechnology programGuangdong provincePlanned scienceTechnology project
© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.